{"messages":[{"status":"ok","category":"all"}], "collection":[{"title":"Poor sleep is robustly correlated with accelerated aging but the evidence for causation is mixed","authors":"Whitman, E. T.; Prather, A. A.; Mutz, J.; Arseneault, L.; Baranger, D. A. A.; Elliott, M. L.; Fisher, H. L.; Ireland, D.; Knodt, A. R.; Kositzke, C.; Leng, Y.; Reuben, A.; Sugden, K.; Williams, B. S.; Xie, J. K.; Yuan, A.; Moffitt, T. E.; Caspi, A.; Hariri, A. R.; the Alzheimer's Disease Neuroimaging Initiative,  ","author_corresponding":"Ethan T. Whitman","author_corresponding_institution":"Department of Psychology and Neuroscience, Duke University, Durham, NC, USA","doi":"10.64898\/2026.07.02.26357135","date":"2026-07-06","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"psychiatry and clinical psychology","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2026\/07\/06\/2026.07.02.26357135.source.xml","abstract":"Sleep gets worse with age and is correlated with risk for disease and mortality. The possibility that poor sleep causes aging to accelerate has prompted interest in improving sleep to slow aging and prevent disease. However, the existing evidence on the link between poor sleep and accelerated aging is unclear. Here, we tested for correlation and causation between poor sleep and accelerated aging using five independent datasets of adults (total N > 64,000). We found strong evidence for a correlation between poor sleep and fast aging that is consistent across young, middle, and late adulthood and across aging biomarkers derived from different tissues and modalities. We found that this correlation is robust to the influence of chronic disease burden, but not to the influence of shared genetic and early environmental factors among twins. Finally, we found mixed evidence for a causal influence of poor sleep on accelerated aging using Mendelian randomization. Our findings indicate that the correlation between poor sleep and accelerated aging is highly robust; however, the claim that poor sleep causes aging to accelerate is not consistently supported.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Global COVID-19 vaccination uptake across the emergency and early post-emergency periods, 2021-2024","authors":"Brooks, D. J.; Germann, A.; Craw, L.; Dumolard, L.; Nedelec, Y.; Acma, A.; Schultz, C.; Mboussou, F.; Atagbaza, A.; Doshi, R. H.; Pastore, R.; Contreras, M.; Velandia Gonzalez, M.; Leon, R.; Mere, O.; Kissa, J.; Emmanuel Njambe, T. O.; Gonzales, G.; Bayutas, B.; Chang Blanc, D.; Von Dobschuetz, S.; Wilder-Smith, A.; Gacic-Dobo, M.; Van Kerkhove, M. D.; O'Brien, K. L.","author_corresponding":"Katherine L O'Brien","author_corresponding_institution":"World Health Organization, Headquarters, Geneva, Switzerland","doi":"10.64898\/2026.07.02.26356844","date":"2026-07-06","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"public and global health","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2026\/07\/06\/2026.07.02.26356844.source.xml","abstract":"COVID-19 vaccination helped change the course of the pandemic and remains critical for protecting high-risk groups. We analyzed data submitted to WHO to describe COVID-19 vaccination coverage during the emergency period from 2021-2023 and annual uptake in 2024, the first post-emergency calendar year after the Public Health Emergency of International Concern designation was lifted. By end-2023, global complete primary series coverage reached 65% in the total population, 82% among older adults, and 91% among health and care workers (HCWs), across reporting countries. Booster coverage was lower, at 33%, 60%, and 69%, respectively. Across indicators, disparities by country income group and region emerged early and persisted through 2024. In 2024, vaccination of older adults and HCWs was limited and heterogeneous. These findings underscore the need for stronger, sustainably financed adult immunization platforms and associated monitoring systems to enhance life-course vaccination benefits and to support future outbreak, epidemic, and pandemic responses.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"COVID-19 mRNA Vaccination Reduces Guillain-Barre Syndrome Risk: Evidence from a Large Longitudinal Cohort Study","authors":"Li, J.; Pan, Y.; Han, Y.; Zhou, C.; Zhao, L.; He, Y.","author_corresponding":"Yongqun He","author_corresponding_institution":"Unit for Laboratory Animal Medicine, University of Michigan Medical School","doi":"10.64898\/2026.07.02.26357163","date":"2026-07-06","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"public and global health","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2026\/07\/06\/2026.07.02.26357163.source.xml","abstract":"Abstract The association between COVID-19 vaccination and Guillain-Barre syndrome (GBS) has been previously investigated with inconsistent results, largely due to limited data and lack of concurrent controls. To address this problem, a large longitudinal cohort study was conducted using National COVID Cohort Collaborative (N3C) data. While COVID-19 infection was associated with increased GBS occurrence, COVID-19 vaccination was associated with significantly reduced GBS risk relative to unexposed (unvaccinated and uninfected) control, corresponding to a 61% lower 30-day risk (incidence risk ratio: IRR = 0.39, P < 0.01), consistent with multivariable Cox regression showing a similar reduction (adjusted hazard ratio: aHR = 0.41, P < 0.01). This protective association was observed only among recipients of mRNA vaccines (BNT162b2: IRR = 0.38, P < 0.01; mRNA-1273: IRR = 0.24, P < 0.01), but not among recipients of adenoviral-vector vaccines (IRR = 1.38, P > 0.05). Prior COVID-19 vaccination also reduced infection-associated GBS risk. Additional factors associated with GBS risk included sex, vaccine dose, and pre-existing comorbidities such as stroke, neurological disorders, and autoimmune diseases. Overall, our N3C large-scale study provides evidence that COVID-19 mRNA vaccination reduces GBS risk, supporting the safety profile of mRNA vaccines and warranting further mechanistic investigation.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Effect of Intensive vs Standard Blood Pressure Control According to APOE \u03b54 Genotype: A Secondary Analysis of SPRINT","authors":"Xu, Y.; Pruzin, J.; Greene, T.; Williamson, J.; Reboussin, D.; Pajewski, N.; Klein, M.; Yau, W.-Y.; Reiman, E. M.; Supiano, M.; Ashton, N.; Chhatwal, J.; Bress, A. P.","author_corresponding":"Yizhe Xu","author_corresponding_institution":"University of Utah","doi":"10.64898\/2026.07.02.26357167","date":"2026-07-06","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"neurology","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2026\/07\/06\/2026.07.02.26357167.source.xml","abstract":"Importance: Apolipoprotein E (APOE) {varepsilon}4 is the strongest genetic risk factor for sporadic dementia, yet whether the benefits of intensive systolic blood pressure (SBP) control differ by APOE {varepsilon}4 carrier status remains unknown. This is among the first randomized evaluations of intensive SBP control on all-cause dementia by APOE {varepsilon}4 status in US adults without diabetes. Objective: To compare effects of intensive vs standard SBP control on incident all-cause probable dementia between APOE {varepsilon}4 carriers and non-carriers. Design, Setting, and Participants: Secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), a multicenter randomized trial of adults [&ge;]50 years with hypertension and increased cardiovascular risk, but without diabetes, prior stroke, or dementia. Primary cognitive follow-up ended July 2018. Participants were further followed with telephone-based outcome assessment from 2019 through 2023. Interventions: Intensive SBP control (goal <120 mm Hg) vs standard SBP control (goal <140 mm Hg). Main Outcomes and Measures: The primary outcome was all-cause probable dementia. Secondary outcomes were mild cognitive impairment (MCI); MCI or dementia; MCI, dementia, or death; and all-cause mortality. APOE {varepsilon}4 status was the primary effect modifier. Results: Of 9,361 randomized participants, 8,390 (89.6%) had APOE genotyping (29% {varepsilon}4 carriers); 7,733 (82.6%) had both genotype and outcome data (mean age, 68 years; 36% female; 28% Non-Hispanic Black). Over a median follow-up of 5.1 years, dementia rates (intensive vs standard) were 9.7 vs 13.2 per 1,000 person-years among {varepsilon}4 carriers (hazard ratio [HR], 0.73; 95% CI, 0.51-1.04) and 6.1 vs 6.7 among non-carriers (HR, 0.91; 95% CI, 0.67-1.23; P-interaction = .35). Four-year risk differences were -1.7% (95% CI, -3.4% to 0%; number needed to treat, 59) among carriers and 0.2% (95% CI, -0.6% to 1%) among non-carriers (P-interaction = .045). Patterns were similar for the composite of MCI or dementia; effects on MCI were similar between APOE {varepsilon}4 subgroups. Conclusions and Relevance: Among US adults at high cardiovascular risk, intensive SBP control yielded larger absolute risk reduction in dementia among APOE {varepsilon}4 carriers than non-carriers; relative effects were similar. These findings may inform APOE {varepsilon}4-stratified blood pressure management for dementia prevention.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Automated Multisource Electronic Frailty Index in Acute Ischemic Stroke: Development and Clinical Utility","authors":"Lin, S.; Foo, W. T.; Ng, Y. S.; Chang, H. M.; laura, T. B. G.; De Silva, D. A.","author_corresponding":"Shawn Lin","author_corresponding_institution":"National Neuroscience Institute","doi":"10.64898\/2026.07.01.26357083","date":"2026-07-06","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"neurology","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2026\/07\/06\/2026.07.01.26357083.source.xml","abstract":"Background: Frailty is common in acute ischemic stroke (AIS) and predicts poor outcomes, but is not routinely captured in acute stroke care. Manual frailty tools are difficult to apply consistently in busy inpatient settings, while existing electronic frailty indices (eFIs) often rely on limited data modalities. We developed a scalable pre-stroke electronic frailty index (eFI) using multisource electronic medical record (EMR) data and evaluated its clinical utility. Methods: We conducted a retrospective cohort study of AIS admissions to Singapore General Hospital from July 1, 2024, to January 31, 2025. A fully automated pipeline derived an eFI from EMR data over a 3-year lookback period, incorporating ICD-10 codes, vital signs, anthropometry, laboratory results, medications, and free-text documentation processed using artificial intelligence?augmented extraction of predefined, clinically interpretable deficits. Candidate variables were screened using a validated 10-step frailty index framework and refined by multidisciplinary expert consensus. Results: Among 501 AIS cases, the pipeline generated 75 candidate variables and a final 33-variable eFI, with scores derived for 492 cases (98.2%). Frail patients had greater premorbid disability, higher stroke severity, longer hospitalization, greater rehabilitation use, worse discharge disability, higher 30-day readmission, and higher cumulative post-discharge mortality. In multivariable analyses adjusted for age, sex, NIHSS, premorbid mRS, and reperfusion therapy, each 0.1-unit increase in eFI was associated with mortality beyond 90 days after discharge (adjusted HR, 1.47; 95% CI, 1.19?1.81), 30-day readmission (adjusted OR, 1.91; 95% CI, 1.43?2.59), longer hospital stay (?, 2.8 days; 95% CI, 1.4?4.2), and discharge to inpatient rehabilitation rather than home (adjusted RRR, 1.66; 95% CI, 1.27?2.16). Conclusions: In a well-documented acute stroke service supported by comprehensive longitudinal EMR data, automated multisource eFI derivation was feasible and clinically informative in AIS, capturing baseline vulnerability beyond conventional stroke measures and supporting frailty-informed risk stratification and discharge planning.","funder":"NA","published":"NA","server":"medRxiv"}]}